Prognostic significance for recurrence of fibroblast growth factor receptor 2 in intrahepatic cholangiocarcinoma patients undergoing curative hepatic resection

Inhibition of FGFR2 enhances chemosensitivity to gemcitabine in cholangiocarcinoma through the AKT/mTOR and EMT signaling pathways

(2022) Rattanaporn Jaidee et al.   LIFE SCIENCES

Geospatial immune heterogeneity reflects the diverse tumor-immune interactions in intrahepatic cholangiocarcinoma

(2022) Youpei Lin et al.   Cancer Discovery

Multimodal profiling of biliary tract cancers to detect potentially actionable biomarkers and differences in immune signatures between subtypes.

(2021) Kabir Mody et al.   JOURNAL OF CLINICAL ONCOLOGY

Comparative Genomic Analysis of Intrahepatic Cholangiocarcinoma: Biopsy Type, Ancestry, and Testing Patterns

(2021) Mason A. Israel et al.   ONCOLOGIST

Impact of Immune Response on Outcomes in Hepatocellular Carcinoma: Association with Vascular Formation

(2020) Shinji Itoh et al.   HEPATOLOGY

INCB054828 (pemigatinib), a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3, displays activity against genetically defined tumor models

(2020) Phillip C. C. Liu et al.   PLoS One

Skeletal muscle mass predicts the prognosis of patients with intrahepatic cholangiocarcinoma

(2019) Kyohei Yugawa et al.   AMERICAN JOURNAL OF SURGERY

FGFR2 Promotes Expression of PD-L1 in Colorectal Cancer via the JAK/STAT3 Signaling Pathway

(2019) Piao Li et al.   JOURNAL OF IMMUNOLOGY

Fibroblast Growth Factor Receptors (FGFRs): Structures and Small Molecule Inhibitors

(2019) Shuyan Dai et al.   Cells

Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH -Mutant Molecular Profiles

(2017) Farshad Farshidfar et al.   Cell Reports

Mechanism of FGF receptor dimerization and activation

(2016) Sarvenaz Sarabipour et al.   Nature Communications

Evaluation of Fibroblast Growth Factor Receptor 2 Expression, Heterogeneity and Clinical Significance in Gastric Cancer

(2015) Nayoung Han et al.   PATHOBIOLOGY

Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer

(2010) Juan Valle et al.   NEW ENGLAND JOURNAL OF MEDICINE